第49届圣安东尼奥乳腺癌研讨会（SABCS 2026）将于当地时间2026年12月8-11日在美国得克萨斯州圣安东尼奥举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。日前，SABCS官网已披露本届大会摘要标题。
编者按：第49届圣安东尼奥乳腺癌研讨会（SABCS 2026）将于当地时间2026年12月8-11日在美国得克萨斯州圣安东尼奥举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。日前，SABCS官网已披露本届大会摘要标题。
肿瘤瞭望特整理会议第三天（12月10日）精彩内容，涵盖焦点壁报、大会特邀讲座、全体大会专场、案例讨论、壁报展示、特别会议、辩论、教育专场及Mini口头报告等，并将并将全体大会2（General Session 2）及Mini口头报告（Rapid Fire 5和Rapid Fire 6）摘要题目进行整理，以便读者快速了解会议动态，敬请关注后续详细报道！
五场焦点壁报专场：1、焦点壁报13：三阴性乳腺癌；2、焦点壁报5：优化与拓展HR+转移性乳腺癌的治疗武器库；3、焦点壁报6：我们是否倾听所有患者的意见？数字化工具、患者报告的结局和乳腺癌的差异；4、焦点壁报7：动态液体活检：从分子残留病灶到治疗干预；5、焦点壁报8：乳腺癌的新见解。
一场大会特邀讲座：William L. McGuire奖。
一场全体大会专场：全体大会2。
两场获奖讲座：1、AACR乳腺癌研究杰出讲座；2、乳腺癌杰出研究者奖。
一场案例讨论：分子肿瘤委员会。
两场壁报展示：1、Poster Session 3；2、Poster Session 4。
三场Mini口头报告：1、Rapid Fire 8；2、Rapid Fire 5；3、Rapid Fire 6。
一场特别会议：政策、可及性与金融毒性-理解差异的驱动因素。
两场前沿进展：1、前沿进展2：用放射配体疗法扩大乳腺癌的治疗库；2、前沿进展3：创新转化方法：AACR年会亮点。
一场辩论专场：转化研究争议：MRD与ctDNA在乳腺癌中的临床应用价值。
五场教育专场：1、教育专场12：ADC（抗体偶联药物）相关争议；2、教育专场13：新辅助内分泌治疗角色的演变；3、教育专场14：超越年龄-优化老年乳腺癌诊疗的实用方法；4、教育专场15：宿主的作用：重新审视肿瘤微环境；5、教育专场16：放疗与新兴全身治疗：是友还是敌？
专场：General Session 2
时间：12月10日9:30 AM–11:45 AM CST
地点：Hall 1
摘要号：GS2-1
Omission of Breast Surgery in HER2-Positive Primary Breast Cancer Achieving Clinical Complete Response After Anti-HER2-Based Therapy: Primary Results From the AMATERAS-BC Prospective Phase III Trial (JCOG1806)
HER2阳性原发性乳腺癌患者在接受抗HER2治疗后达到临床完全缓解，免除乳腺手术：AMATERAS-BC前瞻性III期临床试验（JCOG1806）的主要结果
讲者：Tomomi Fujisawa, Gunma Prefectural Cancer Center, Gunma, Japan
摘要号：GS2-3
Prospect : post-operative radiotherapy omission in selected patients with early breast cancer trial (ANZ 1002). Final results.
PROSPECT：在特定早期乳腺癌患者中豁免术后放疗（ANZ 1002）的最终结果
讲者：Bruce Mann, The Royal Melbourne Hospital, Parkville, Australia
摘要号：GS2-4
Neonod2 trial: initial oncologic outcomes following omission of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy
Neonod2研究：乳腺癌伴前哨淋巴结微转移患者在新辅助治疗后免除腋窝淋巴结清扫的初步肿瘤学结局
讲者：Corrado Tinterri, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
摘要号：GS2-5
Results of the POSNOC Trial: Omission of Axillary Treatment in Patients Undergoing Breast-Conserving Surgery or Mastectomy with One or Two Sentinel Node Macrometastases
POSNOC研究结果：伴1-2枚前哨淋巴结宏转移的患者在接受保乳手术或全乳切除术后省略腋窝治疗的结局
讲者：Amit Goyal, Royal Derby Hospital, Derby, United Kingdom
专场：Rapid Fire 5
时间：12月10日4:30 PM-5:30 PM CST
地点：Stars at Night 1-2
摘要号：RF5-2
De-escalated Denosumab (Every 12 versus Every 4 Weeks) Maintains Efficacy for Prevention of Symptomatic Skeletal Events in Patients with Bone Metastases: Breast Cancer Stratum from the Randomized Phase-III Non-Inferiority REDUSE Trial (SAKK 96/12)
地舒单抗降阶梯给药（每12周对比每4周）维持治疗对骨转移患者症状性骨骼事件的预防疗效：随机III期非劣效性REDUSE研究（SAKK 96/12）乳腺癌队列的结果
讲者：Andreas Müller, Kantonsspital Winterthur, Winterthur, Switzerland
摘要号：RF5-3
Pink! Leben: a randomized controlled trial of an acceptance and commitment therapy-based digital intervention for psychological distress in breast cancer patients across treatment phases
Pink! Leben：一项基于接纳与承诺疗法（ACT）的数字干预用于缓解乳腺癌患者各治疗阶段心理痛苦的随机对照试验
讲者：Christian Schem, Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany
摘要号：RF5-4
Quality of life for patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes within the OPTIMA trial
OPTIMA研究中40岁及以上、ER+/HER2-且腋窝淋巴结受累0-9枚的早期乳腺癌患者的生活质量
讲者：Janet Audrey Dunn, University of Warwick, Coventry, United Kingdom
摘要号：RF5-5
Temperature-controlled hand-foot cooling prevents chemotherapy-induced polyneuropathy (cipn): updated real-world data collection in 600 patients
温控手足冷却可预防化疗诱导的周围神经病变（CIPN）：600例患者的最新真实世界数据
讲者：Athina Kostara, MVZ Medical Center Duesseldorf, Duesseldorf, Germany
摘要号：RF5-6
The role of estrogen plus progestogen on breast cancer incidence: a systematic review and meta-analysis of randomized clinical trials
雌激素联合孕激素对乳腺癌发病率的影响：随机临床试验的系统综述与荟萃分析
讲者：Margaret S Pichardo, University of Pennsylvania,, Philadelphia, PA
摘要号：RF5-7
Social drivers, age-at-onset, and later stage at diagnosis in association with aggressive RNA-based breast cancer subtypes among Black women
黑人女性中社会驱动因素、发病年龄及确诊时较晚分期与基于RNA的侵袭性乳腺癌亚型的相关性
讲者：Sarah C Van Alsten, University of North Carolina at Chapel Hill, Chapel Hill, NC
专场：Rapid Fire 6
时间：12月10日5:30 PM–6:30 PM CST
地点：Stars at Night 1-2
摘要号：RF6-1
Interim event-free survival with peri-operative immune checkpoint inhibition and cryoablation in residual triple-negative breast cancer
残余三阴性乳腺癌围手术期免疫检查点抑制和冷冻消融治疗的中期无事件生存结果
讲者：Heather L McArthur, UTSW, Dallas, TX
摘要号：RF6-2
Breast-mri trial: the paradox of preoperative breast mri — more surgery, no detectable survival benefit in a randomized trial
Breast-MRI试验：术前乳腺MRI的悖论——随机试验显示更多手术干预，但未观察到生存获益
讲者：Bruna S Mota, ICESP, Sao Paulo, Brazil
摘要号：RF6-3
Technical outcomes of node marking and targeted axillary dissection after neoadjuvant chemotherapy in node-positive breast cancer: results from 1295 participants in the ATNEC trial
淋巴结阳性乳腺癌患者新辅助化疗后淋巴结标记与靶向腋窝清扫的技术结局：ATNEC研究1295例参与者的结果
讲者：Amit Goyal, Royal Derby Hospital, Derby, United Kingdom
摘要号：RF6-4
Prediction of pathological tumor size in 2,138 breast cancer patients treated with breast-conserving surgery: comparative analysis of preoperative imaging modalities in the prospective multicenter MELODY (EUBREAST-4 / iBRA-NET / AGO-B-062) study
2138例接受保乳手术的乳腺癌患者病理肿瘤大小的预测：前瞻性多中心MELODY（EUBREAST-4 / iBRA-NET / AGO-B-062）研究中术前影像学检查方式的比较分析
讲者：Nikolas Tauber, University of Luebeck, Luebeck, Germany
摘要号：RF6-5
Axillary Radiotherapy as an Alternative to Axillary Lymph Node Dissection in Sentinel Node-Positive Breast CancerPatientsAfter Neoadjuvant Therapy: Three-Year Outcomes from the ADARNAT Pilot Randomized Trial
腋窝放疗作为新辅助治疗后前哨淋巴结阳性乳腺癌患者腋窝淋巴结清扫的替代方案：ADARNAT先导性随机试验的三年结果
讲者：Amparo Garcia-Tejedor, Bellvitge Hospital, L'Hospitalet de Llobregat, Spain
摘要号：RF6-6
One-week or three-week Adjuvant Radiation in Breast Cancer (OTHAR) – A Phase III Non-Inferiority Randomized controlled Trial- Early outcomes and Acute Toxicity Results
乳腺癌一周或三周辅助放疗（OTHAR）——一项III期非劣效性随机对照试验：早期结局与急性毒性结果
讲者：Supriya Mallick, National Cancer Institute-All India Institute of Medical Sciences,New Delhi, New Delhi, India
摘要号：RF6-7
Oncological safety of breast-conserving surgery following neo-adjuvant chemotherapy in locally advanced breast cancer: Results from a randomized controlled trial
局部晚期乳腺癌新辅助化疗后保乳手术的肿瘤学安全性：一项随机对照试验的结果
讲者：Ankita Manan Sheth, Tata Memorial Hospital, Mumbai, India